SMARCB1 and neoplasm: Also, interim results from a phase I study of the EZH2 inhibitor tazemetostat in relapsed or refractory INI1-negative tumors (e.g., epithelioid sarcoma, extraskeletal myxoid chondrosarcoma, dedifferentiated chordoma) or synovial sarcoma showed promising anti-tumor activity (NCT02601937) (Table 2).